HRP20010200B1 - 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors - Google Patents

4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Info

Publication number: HRP20010200B1
Authority: HR; Croatia
Prior art keywords: optionally; carbon; sulfur; nitrogen; mono
Prior art date: 1998-09-17

Application number

HR20010200A

Other languages

English (en)

Croatian (hr)

Inventor

Paul Deninno Michael

Tetteh Magnus-Aryitey George

Benjamin Ruggeri Roger

Thure Wester Ronald

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-17

Filing date

2001-03-16

Publication date

2006-10-31

2001-03-16 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2002-04-30 Publication of HRP20010200A2 publication Critical patent/HRP20010200A2/hr

2006-10-31 Publication of HRP20010200B1 publication Critical patent/HRP20010200B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Cardiology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Child & Adolescent Psychology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

HR20010200A 1998-09-17 2001-03-16 4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors HRP20010200B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10092798P	1998-09-17	1998-09-17
PCT/IB1999/001534 WO2000017165A1 (en)	1998-09-17	1999-09-10	4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Publications (2)

Publication Number	Publication Date
HRP20010200A2 HRP20010200A2 (en)	2002-04-30
HRP20010200B1 true HRP20010200B1 (en)	2006-10-31

Family

ID=22282246

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20010200A HRP20010200B1 (en)	1998-09-17	2001-03-16	4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Country Status (50)

Country	Link
US (2)	US6140343A (xx)
EP (1)	EP1114032B1 (xx)
JP (1)	JP3561474B2 (xx)
KR (1)	KR100422286B1 (xx)
CN (2)	CN1515259A (xx)
AP (1)	AP1345A (xx)
AR (1)	AR030523A1 (xx)
AT (1)	ATE268324T1 (xx)
AU (1)	AU747715B2 (xx)
BG (1)	BG65101B1 (xx)
BR (1)	BR9913855A (xx)
CA (1)	CA2344248C (xx)
CO (1)	CO5290250A1 (xx)
CR (1)	CR6306A (xx)
CU (1)	CU23053A3 (xx)
CZ (1)	CZ2001954A3 (xx)
DE (1)	DE69917790T2 (xx)
DK (1)	DK1114032T3 (xx)
DZ (1)	DZ2891A1 (xx)
EA (1)	EA005761B1 (xx)
EE (1)	EE200100167A (xx)
ES (1)	ES2221420T3 (xx)
GC (1)	GC0000108A (xx)
GE (1)	GEP20032973B (xx)
GT (1)	GT199900147A (xx)
HK (1)	HK1039938A1 (xx)
HR (1)	HRP20010200B1 (xx)
HU (1)	HUP0103512A3 (xx)
ID (1)	ID27838A (xx)
IL (1)	IL141388A0 (xx)
IS (1)	IS2278B (xx)
MA (1)	MA26689A1 (xx)
MY (1)	MY121405A (xx)
NO (1)	NO319781B1 (xx)
NZ (1)	NZ509837A (xx)
OA (1)	OA11651A (xx)
PA (1)	PA8481201A1 (xx)
PE (1)	PE20001054A1 (xx)
PL (1)	PL198124B1 (xx)
PT (1)	PT1114032E (xx)
SI (1)	SI1114032T1 (xx)
SK (1)	SK3532001A3 (xx)
SV (1)	SV1999000150A (xx)
TN (1)	TNSN99170A1 (xx)
TR (1)	TR200100780T2 (xx)
TW (1)	TW502022B (xx)
UA (1)	UA70960C2 (xx)
WO (1)	WO2000017165A1 (xx)
YU (1)	YU18101A (xx)
ZA (1)	ZA200101745B (xx)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6147089A (en) *	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) *	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US7115279B2 (en) *	2000-08-03	2006-10-03	Curatolo William J	Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20060287254A1 (en) *	2001-01-26	2006-12-21	Schering Corporation	Use of substituted azetidinone compounds for the treatment of sitosterolemia
SE0101161D0 (sv) *	2001-03-30	2001-03-30	Astrazeneca Ab	New compounds
JP4334233B2 (ja) *	2001-04-11	2009-09-30	アセロジエニクス・インコーポレイテツド	プロブコールモノエステルによって血漿ｈｄｌコレステロールレベルを上昇させ、ｈｄｌの機能性を改善するための方法
JP3924251B2 (ja)	2001-04-30	2007-06-06	ファイザー・プロダクツ・インク	Ｃｅｔｐ阻害剤の製造法
CZ20033341A3 (cs) *	2001-06-21	2004-10-13	Pfizeráproductsáinc	Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru
EP1269994A3 (en)	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CA2450957A1 (en)	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of dispersions of drugs and neutral polymers
WO2003000238A1 (en)	2001-06-22	2003-01-03	Pfizer Products Inc.	Pharmaceutical compositions of adsorbates of amorphous drug
AU2002361811A1 (en)	2001-12-19	2003-07-09	Atherogenics, Inc.	1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
CN1596240A (zh) *	2001-12-19	2005-03-16	阿特罗吉尼克斯公司	查耳酮衍生物及其治疗疾病的用途
BR0215212A (pt) *	2001-12-21	2004-12-07	Novo Nordisk As	Ativador de carboxamida ou sulfonamida de glicoquinase, composto, composição farmacêutica, e, uso de um composto
BR0307332A (pt) *	2002-02-01	2004-12-07	Pfizer Prod Inc	Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
CA2472028C (en) *	2002-02-01	2010-03-30	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
AR038375A1 (es)	2002-02-01	2005-01-12	Pfizer Prod Inc	Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
DE60320940D1 (de)	2002-02-01	2008-06-26	Pfizer Prod Inc	Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
CA2744893A1 (en) *	2002-06-27	2004-01-08	Novo Nordisk A/S	Aryl carbonyl derivatives as glucokinase activators
US20040053842A1 (en) *	2002-07-02	2004-03-18	Pfizer Inc.	Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) *	2002-07-02	2006-07-04	Pfizer Inc.	CETP inhibitors in combination with antihypertensive agents and uses thereof
WO2004032848A2 (en)	2002-10-04	2004-04-22	Millennium Pharmaceuticals, Inc.	Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en)	2002-10-04	2009-03-17	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) *	2002-10-04	2009-07-16	Millennium Pharmaceuticals, Inc.	PGD2 receptor antagonists for the treatment of inflammatory diseases
MXPA05003660A (es) *	2002-10-21	2005-06-08	Warner Lambert Co	Derivados de quinolina como antagonistas de crth2.
AU2003289207A1 (en) *	2002-12-06	2004-06-30	Kyowa Hakko Kogyo Co., Ltd.	Anti-inflammatory agent
AU2003303239A1 (en) *	2002-12-19	2004-07-14	Atherogenics, Inc.	Process of making chalcone derivatives
US20040132771A1 (en) *	2002-12-20	2004-07-08	Pfizer Inc	Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE461700T1 (de)	2002-12-20	2010-04-15	Pfizer Prod Inc	Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
EP1435356A1 (en) *	2003-01-06	2004-07-07	Warner-Lambert Company LLC	Quinoline derivatives as CRTH2 antagonists
WO2004072042A2 (en) *	2003-02-12	2004-08-26	Carex S.A.	Quinoline derivative and their use for modulation of lxr activity
WO2004082675A1 (en) *	2003-03-17	2004-09-30	Japan Tobacco Inc.	Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
EP2289507A1 (en)	2003-03-17	2011-03-02	Japan Tobacco, Inc.	Pharmaceutical compositions of CETP inhibitors
US20040204450A1 (en) *	2003-03-28	2004-10-14	Pfizer Inc	Quinoline and quinoxaline compounds
JP2006521344A (ja) *	2003-03-28	2006-09-21	ファイザー・プロダクツ・インク	アテローム性動脈硬化症および肥満の治療のためのｃｅｔｐ阻害剤としての１，２，４−置換１，２，３，４−テトラヒドロ−および１，２−ジヒドロ−キノリンおよび１，２，３，４−テトラヒドロ−キノキサリン誘導体
TWI393560B (zh) *	2003-05-02	2013-04-21	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
RS20050890A (xx)	2003-05-30	2007-12-31	Ranbaxy Laboratories Limited,	Supstituisani pirol derivati
CL2004001884A1 (es)	2003-08-04	2005-06-03	Pfizer Prod Inc	Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
EP1653927B1 (en) *	2003-08-04	2012-01-11	Bend Research, Inc.	Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
EP2316447A1 (en)	2003-09-26	2011-05-04	Japan Tobacco, Inc.	Method of inhibiting remnant lipoprotein production
BRPI0414671A (pt) *	2003-09-30	2006-11-21	Pfizer Prod Inc	inibidores da cetp e metabolitos dos mesmos
ES2332051T3 (es)	2003-10-08	2010-01-25	Eli Lilly And Company	Compuestos y procedimientos para tratar dislipidemia.
WO2005046662A2 (en) *	2003-11-07	2005-05-26	Jj Pharma, Inc.	Hdl-boosting combination therapy complexes
JP4834840B2 (ja)	2004-01-06	2011-12-14	ノヴォノルディスクアー／エス	ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
ME02070B (me)	2004-03-05	2013-10-31	Univ Pennsylvania	Postupci za lečenje poremećaja ili bolesti povezanih sa hiperlipidemijom i hiperholesterolemijom uz minimizaciju sporednih efekata
US7262318B2 (en) *	2004-03-10	2007-08-28	Pfizer, Inc.	Substituted heteroaryl- and phenylsulfamoyl compounds
ES2308477T3 (es)	2004-03-26	2008-12-01	Eli Lilly And Company	Compuestos para el tratamiento de la dislipidemia.
UA90269C2 (ru) *	2004-04-02	2010-04-26	Мицубиси Танабе Фарма Корпорейшн	Тетрагидрохинолиновые производные и способ их получения
MY139887A (en) *	2004-04-02	2009-11-30	Mitsubishi Tanabe Pharma Corp	Tetrahydronaphthyridine derivatives and a process for preparing the same.
US20050282812A1 (en) *	2004-06-18	2005-12-22	JONES Zachary	Inhibitors of cholesteryl ester transfer protein
JP2008504266A (ja) *	2004-06-24	2008-02-14	イーライリリーアンドカンパニー	異脂肪血症を治療するための化合物及び方法
KR100859223B1 (ko) *	2004-06-24	2008-09-18	일라이 릴리 앤드 캄파니	이상지혈증 치료를 위한 화합물 및 방법
US20060063828A1 (en) *	2004-06-28	2006-03-23	Weingarten M D	1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US20050288340A1 (en) *	2004-06-29	2005-12-29	Pfizer Inc	Substituted heteroaryl- and phenylsulfamoyl compounds
DOP2005000123A (es)	2004-07-02	2011-07-15	Merck Sharp & Dohme	Inhibidores de cetp
AU2005280058B2 (en) *	2004-08-25	2010-09-02	Essentialis, Inc.	Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US20070149567A1 (en) *	2004-09-23	2007-06-28	Pfizer Inc	Quinoline compounds
US20060063803A1 (en) *	2004-09-23	2006-03-23	Pfizer Inc	4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
KR20070084455A (ko) *	2004-11-23	2007-08-24	워너-램버트 캄파니 엘엘씨	지질혈증 치료용 ｈｍｇｃｏ-ａ 환원효소 억제제로서의7-(2ｈ-피라졸-3-일)-3,5-디히드록시-헵탄산 유도체
US7700774B2 (en) *	2004-12-20	2010-04-20	Dr. Reddy's Laboratories Ltd.	Heterocyclic compounds and their pharmaceutical compositions
KR101238525B1 (ko)	2004-12-31	2013-02-28	레디 유에스 테라퓨틱스 인코포레이티드	Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP2548894A1 (en)	2005-02-03	2013-01-23	Bend Research, Inc.	Pharmaceutical compositions with enhanced performance
UA90706C2 (ru)	2005-02-24	2010-05-25	Милленниум Фармасьютикалз, Инк.	Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2006098394A1 (ja) *	2005-03-14	2006-09-21	Japan Tobacco Inc.	脂質吸収抑制方法および脂質吸収抑制剤
CA2612142A1 (en) *	2005-07-01	2007-01-11	Merck & Co., Inc.	Process for synthesizing a cetp inhibitor
US7999114B2 (en) *	2005-07-08	2011-08-16	Novo Nordisk A/S	Dicycloalkylcarbamoyl ureas as glucokinase activators
JP2009500377A (ja) *	2005-07-08	2009-01-08	ノボ・ノルデイスク・エー／エス	ジシクロアルキルウレア型グルコキナーゼ活性化剤
CN101263131B (zh) *	2005-07-14	2013-04-24	特兰斯特克药品公司	脲葡糖激酶活化剂
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
JP4681526B2 (ja) *	2005-09-29	2011-05-11	田辺三菱製薬株式会社	医薬組成物
JP4531027B2 (ja) *	2005-09-29	2010-08-25	田辺三菱製薬株式会社	医薬組成物
WO2007048027A2 (en)	2005-10-21	2007-04-26	Novartis Ag	Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
KR101329112B1 (ko)	2005-11-08	2013-11-14	랜박시 래보러터리스 리미티드	(3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US7888376B2 (en)	2005-11-23	2011-02-15	Bristol-Myers Squibb Company	Heterocyclic CETP inhibitors
CN103172592B (zh)	2006-01-05	2016-01-06	伊森舍丽斯有限公司	钾atp 通道开放剂的盐及其用途
UY30117A1 (es)	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compuesto amina trisustituido
PE20071025A1 (es)	2006-01-31	2007-10-17	Mitsubishi Tanabe Pharma Corp	Compuesto amina trisustituido
UY30244A1 (es)	2006-03-30	2007-11-30	Tanabe Seiyaku Co	Un proceso para preparar derivados de tetrahidroquinolina
GB0615670D0 (en) *	2006-08-07	2006-09-13	Syngenta Participations Ag	Chemical compounds
US7750019B2 (en)	2006-08-11	2010-07-06	Kowa Company, Ltd.	Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US20100210633A1 (en) *	2006-10-12	2010-08-19	Epix Delaware, Inc.	Carboxamide compounds and their use
EP2094643B1 (en)	2006-12-01	2012-02-29	Bristol-Myers Squibb Company	N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
JP2010513534A (ja) *	2006-12-21	2010-04-30	エージェリオンファーマシューティカルズ，インコーポレイテッド	Ｍｔｐインヒビターおよびコレステロール吸収インヒビターを含む組み合わせを用いて肥満症を処置する方法
US8138185B2 (en) *	2007-01-09	2012-03-20	Novo Nordisk A/S	Urea glucokinase activators
EP2099777B1 (en) *	2007-01-11	2015-08-12	Novo Nordisk A/S	Urea glucokinase activators
CN101220021B (zh) *	2007-01-12	2010-12-08	上海医药工业研究院	4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
US7790737B2 (en)	2007-03-13	2010-09-07	Kowa Company, Ltd.	Substituted pyrimidine compounds and their utility as CETP inhibitors
CN101679309B (zh)	2007-04-13	2012-02-29	兴和株式会社	具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物
CA2692160A1 (en) *	2007-07-02	2009-01-08	Essentialis, Inc.	Salts of potassium atp channel openers and uses thereof
WO2009059943A1 (en)	2007-11-05	2009-05-14	Novartis Ag	4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
MX2010006063A (es)	2007-12-03	2010-07-01	Novartis Ag	Derivados de 4-bencil-amino-pirrolidina 1,2-disustituida como inhibidores de la proteina de transferencia de colesteril-ester (cetp) utiles para el tratamiento de las enfermedades tales como hiperlipidemia o arterioesclerosis.
CA2708364A1 (en)	2007-12-11	2009-06-18	Efrat Ben-Zeev	Carboxamide compounds and their use as chemokine receptor agonists
US8455522B2 (en)	2009-05-15	2013-06-04	Novartis Ag	Benzoxazolone derivatives as aldosterone synthase inhibitors
DK2429995T3 (da)	2009-05-15	2014-04-22	Novartis Ag	Arylpyridiner som aldosteronsyntaseinhibitorer
CN102448928B (zh)	2009-05-28	2014-10-01	诺华股份有限公司	作为中性溶酶(neprilysin)抑制剂的取代的氨基丁酸衍生物
WO2010136493A1 (en)	2009-05-28	2010-12-02	Novartis Ag	Substituted aminopropionic derivatives as neprilysin inhibitors
TWI450896B (zh) *	2009-06-30	2014-09-01	Lilly Co Eli	反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
WO2011061168A1 (en)	2009-11-17	2011-05-26	Novartis Ag	Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011064376A1 (en)	2009-11-30	2011-06-03	Novartis Ag	Imidazole derivatives as aldosterone synthase inhibitors
JP2013528172A (ja)	2010-05-21	2013-07-08	ファイザー・インク	２−フェニルベンゾイルアミド
US8877815B2 (en)	2010-11-16	2014-11-04	Novartis Ag	Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012101142A1 (en)	2011-01-26	2012-08-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method for assessing a subject's risk of having a cardiovascular disease.
WO2012120414A2 (en)	2011-03-04	2012-09-13	Pfizer Inc.	Edn3-like peptides and uses thereof
AR086931A1 (es)	2011-06-17	2014-01-29	Merck Sharp & Dohme	Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth
TWI537262B (zh) *	2011-08-17	2016-06-11	美國禮來大藥廠	供治療糖尿病使用之新穎１，２，３，４－四氫喹啉衍生物
EP2744803A2 (en)	2011-08-18	2014-06-25	Dr. Reddy's Laboratories Ltd.	Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
IN2014CN02290A (xx)	2011-09-27	2015-06-19	Reddys Lab Ltd Dr
MX347400B (es)	2012-06-29	2017-04-18	Univ Nac Autónoma De México	Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
HUE038248T2 (hu)	2013-02-14	2018-10-29	Novartis Ag	Helyettesített biszfenil-bután-foszfonsav származékok, mint NEP (semleges endopeptidáz) inhibitorok
WO2014170786A1 (en)	2013-04-17	2014-10-23	Pfizer Inc.	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
UY35671A (es)	2013-07-25	2015-02-27	Novartis Ag	Bioconjugados de polipéptidos de apelina sintética
TW201536814A (zh)	2013-07-25	2015-10-01	Novartis Ag	用於治療心臟衰竭之合成環狀多肽
KR102454984B1 (ko) *	2014-08-28	2022-10-17	뉴암스테르담 파마 비.브이.	콜레스테릴 에스테르 전달 단백질 억제제 및 HMG CoA 환원효소 억제제를 포함한 약제학적 조성물 및 치료적 조합
RU2746405C2 (ru)	2014-08-29	2021-04-13	Тес Фарма С.Р.Л.	ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
WO2016055901A1 (en)	2014-10-08	2016-04-14	Pfizer Inc.	Substituted amide compounds
EP3247405B1 (en)	2015-01-23	2019-07-17	Novartis AG	Synthetic apelin fatty acid conjugates with improved half-life
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
JP2021526130A (ja)	2018-06-12	2021-09-30	ブイティーブイ・セラピューティクス・エルエルシー	インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用
KR20210116548A (ko)	2019-01-18	2021-09-27	아스트라제네카 아베	Pcsk9 억제제 및 이의 이용 방법
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5231102A (en) *	1989-03-08	1993-07-27	Merck Sharp & Dohme, Ltd.	Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) *	1990-06-18	1994-01-04	E. R. Squibb & Sons, Inc.	Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en)	1990-11-26	1995-03-28	E. R. Squibb & Sons, Inc.	Indane and quinoline derivatives
KR920014799A (ko) *	1991-01-18	1992-08-25	나오가따 다이도	신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
US5288725A (en) *	1992-10-15	1994-02-22	Merck & Co., Inc.	Pyrroloquinoline Bradykinin antagonist
HRP970330B1 (en) *	1996-07-08	2004-06-30	Bayer Ag	Cycloalkano pyridines
DE19627431A1 (de)	1996-07-08	1998-01-15	Bayer Ag	Heterocyclisch kondensierte Pyridine
GT199900147A (es) *	1998-09-17	1999-09-06		1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en)	1998-09-17	2000-11-14	Pfizer Inc.	Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6462091B1 (en)	1998-12-23	2002-10-08	G.D. Searle & Co.	Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications

1999
- 1999-09-06 GT GT199900147A patent/GT199900147A/es unknown
- 1999-09-07 US US09/391,313 patent/US6140343A/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481201A patent/PA8481201A1/es unknown
- 1999-09-08 GC GCP1999273 patent/GC0000108A/xx active
- 1999-09-10 CU CU20010051A patent/CU23053A3/es unknown
- 1999-09-10 CO CO99057641A patent/CO5290250A1/es not_active Application Discontinuation
- 1999-09-10 YU YU18101A patent/YU18101A/sh unknown
- 1999-09-10 CN CNA2004100049599A patent/CN1515259A/zh active Pending
- 1999-09-10 AR ARP990104554A patent/AR030523A1/es active IP Right Grant
- 1999-09-10 TR TR2001/00780T patent/TR200100780T2/xx unknown
- 1999-09-10 PT PT99940426T patent/PT1114032E/pt unknown
- 1999-09-10 ID IDW20010621A patent/ID27838A/id unknown
- 1999-09-10 NZ NZ509837A patent/NZ509837A/xx unknown
- 1999-09-10 DK DK99940426T patent/DK1114032T3/da active
- 1999-09-10 AT AT99940426T patent/ATE268324T1/de not_active IP Right Cessation
- 1999-09-10 KR KR10-2001-7003416A patent/KR100422286B1/ko not_active IP Right Cessation
- 1999-09-10 SK SK353-2001A patent/SK3532001A3/sk unknown
- 1999-09-10 BR BR9913855-7A patent/BR9913855A/pt not_active Application Discontinuation
- 1999-09-10 WO PCT/IB1999/001534 patent/WO2000017165A1/en active IP Right Grant
- 1999-09-10 EA EA200100249A patent/EA005761B1/ru not_active IP Right Cessation
- 1999-09-10 JP JP2000574075A patent/JP3561474B2/ja not_active Expired - Fee Related
- 1999-09-10 ES ES99940426T patent/ES2221420T3/es not_active Expired - Lifetime
- 1999-09-10 GE GEAP19995804A patent/GEP20032973B/en unknown
- 1999-09-10 DE DE69917790T patent/DE69917790T2/de not_active Expired - Fee Related
- 1999-09-10 PE PE1999000922A patent/PE20001054A1/es not_active Application Discontinuation
- 1999-09-10 AU AU54403/99A patent/AU747715B2/en not_active Ceased
- 1999-09-10 IL IL14138899A patent/IL141388A0/xx not_active IP Right Cessation
- 1999-09-10 CN CN99811014A patent/CN1318057A/zh active Pending
- 1999-09-10 EE EEP200100167A patent/EE200100167A/xx unknown
- 1999-09-10 OA OA1200100062A patent/OA11651A/en unknown
- 1999-09-10 AP APAP/P/2001/002100A patent/AP1345A/en active
- 1999-09-10 TW TW088115688A patent/TW502022B/zh not_active IP Right Cessation
- 1999-09-10 CA CA002344248A patent/CA2344248C/en not_active Expired - Fee Related
- 1999-09-10 PL PL346830A patent/PL198124B1/pl not_active IP Right Cessation
- 1999-09-10 HU HU0103512A patent/HUP0103512A3/hu unknown
- 1999-09-10 SI SI9930595T patent/SI1114032T1/xx unknown
- 1999-09-10 CZ CZ2001954A patent/CZ2001954A3/cs unknown
- 1999-09-10 SV SV1999000150A patent/SV1999000150A/es not_active Application Discontinuation
- 1999-09-10 EP EP99940426A patent/EP1114032B1/en not_active Expired - Lifetime
- 1999-09-10 UA UA2001031791A patent/UA70960C2/uk unknown
- 1999-09-10 MY MYPI99003926A patent/MY121405A/en unknown
- 1999-09-13 MA MA25766A patent/MA26689A1/fr unknown
- 1999-09-13 TN TNTNSN99170A patent/TNSN99170A1/fr unknown
- 1999-09-13 DZ DZ990191A patent/DZ2891A1/xx active
2000
- 2000-09-27 US US09/671,221 patent/US6489478B1/en not_active Expired - Fee Related
2001
- 2001-02-14 CR CR6306A patent/CR6306A/es unknown
- 2001-02-23 IS IS5858A patent/IS2278B/is unknown
- 2001-03-01 ZA ZA200101745A patent/ZA200101745B/en unknown
- 2001-03-16 NO NO20011349A patent/NO319781B1/no not_active IP Right Cessation
- 2001-03-16 HR HR20010200A patent/HRP20010200B1/xx not_active IP Right Cessation
- 2001-04-10 BG BG105429A patent/BG65101B1/bg unknown
2002
- 2002-02-26 HK HK02101447.5A patent/HK1039938A1/zh unknown

Also Published As

Publication number	Publication date
MY121405A (en)	2006-01-28
DK1114032T3 (da)	2004-08-16
GC0000108A (en)	2005-06-29
IS5858A (is)	2001-02-23
HRP20010200A2 (en)	2002-04-30
EE200100167A (et)	2002-06-17
SK3532001A3 (en)	2001-12-03
TNSN99170A1 (fr)	2005-11-10
BG65101B1 (bg)	2007-02-28
KR20010085814A (ko)	2001-09-07
AU5440399A (en)	2000-04-10
OA11651A (en)	2004-12-07
BG105429A (en)	2001-12-29
NO20011349L (no)	2001-05-14
WO2000017165A1 (en)	2000-03-30
CO5290250A1 (es)	2003-06-27
US6140343A (en)	2000-10-31
CR6306A (es)	2003-08-28
SV1999000150A (es)	2000-06-06
PE20001054A1 (es)	2000-10-14
CN1318057A (zh)	2001-10-17
GT199900147A (es)	1999-09-06
EP1114032B1 (en)	2004-06-02
ES2221420T3 (es)	2004-12-16
PT1114032E (pt)	2004-09-30
AR030523A1 (es)	2003-08-27
HK1039938A1 (zh)	2002-05-17
CN1515259A (zh)	2004-07-28
ID27838A (id)	2001-04-26
KR100422286B1 (ko)	2004-03-11
PL198124B1 (pl)	2008-05-30
EA005761B1 (ru)	2005-06-30
JP3561474B2 (ja)	2004-09-02
MA26689A1 (fr)	2004-12-20
PA8481201A1 (es)	2000-09-29
DE69917790D1 (de)	2004-07-08
ATE268324T1 (de)	2004-06-15
YU18101A (sh)	2004-05-12
TW502022B (en)	2002-09-11
GEP20032973B (en)	2003-05-27
HUP0103512A2 (hu)	2002-02-28
NZ509837A (en)	2002-11-26
EP1114032A1 (en)	2001-07-11
CA2344248C (en)	2007-01-09
TR200100780T2 (tr)	2001-07-23
NO319781B1 (no)	2005-09-12
CA2344248A1 (en)	2000-03-30
IS2278B (is)	2007-09-15
DZ2891A1 (fr)	2003-12-15
AP2001002100A0 (en)	2001-03-31
PL346830A1 (en)	2002-02-25
EA200100249A1 (ru)	2001-08-27
ZA200101745B (en)	2002-05-02
BR9913855A (pt)	2001-07-24
CU23053A3 (es)	2005-06-24
AP1345A (en)	2004-12-15
CZ2001954A3 (cs)	2001-12-12
UA70960C2 (uk)	2004-11-15
SI1114032T1 (xx)	2004-12-31
AU747715B2 (en)	2002-05-23
US6489478B1 (en)	2002-12-03
HUP0103512A3 (en)	2002-03-28
NO20011349D0 (no)	2001-03-16
DE69917790T2 (de)	2005-06-09
IL141388A0 (en)	2002-03-10
JP2002526476A (ja)	2002-08-20

Publication	Publication Date	Title
HRP20010200B1 (en)	2006-10-31	4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
EA200100755A1 (ru)	2001-12-24	4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты
RS52397B (en)	2013-02-28	PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS
PE20010635A1 (es)	2001-08-15	Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
CO5370678A1 (es)	2004-02-27	1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas
LV12712A (lv)	2001-09-20	Inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodekstrin and method
YU48390B (sh)	1998-07-10	Novi derivati 2-anilinopirimidina, postupak za njihovo dobijanje i sredstva za uništavanje štetočina, koja sadrže ove derivate
ES2188264T3 (es)	2003-06-16	Antagonistas del receptor del neuropeptido y5.
MEP24208A (en)	2010-06-10	Derivatives of dioxane-2-alkyl carbamates, preparation method thereof and application of same in therapeutics
CA2101104A1 (en)	1994-01-24	Amino acid linked nitrogen mustard derivatives and their use as prodrugs in the treatment of tumors
RS50012B (sr)	2008-09-29	Agonisti prostaglandina i njihova upotreba u lečenju oboljenja kostiju
RS50540B (sr)	2010-05-07	Substituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga
RS52058B (en)	2012-04-30	MACROCYCLIC HEPATITIS VIRUS INHIBITORS C
YU108791A (sh)	1994-01-20	Pirazolopirimidinon antianginalna jedinjenja
WO2000005223A3 (en)	2001-07-12	Heterocyclic derivatives and their use as integrin inhibitors
ECSP045078A (es)	2004-06-28	Tiofen- y tiazolsulfonamidas como agentes antineoplásicos
DK1113011T3 (da)	2006-11-27	Aminotetrazol-derivater, der er anvendelige som nitrogenoxidsynthaseinhibitorer
ES2062143T3 (es)	1994-12-16	Derivados de pirrol sustituidos con grupos acriloilo y procedimiento para su preparacion.
DOP2001000242A (es)	2002-05-15	Derivados de fenoxibencilamina como ssri
PE107899A1 (es)	1999-11-17	Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
HRP20030610B1 (en)	2006-02-28	Process for the preparation of mesylates of piperazine derivatives
YU58301A (sh)	2004-05-12	2-aminopiridini koji sadrže supstituente sa kondenzovanim prstenom
MXPA02012411A (es)	2003-04-25	Piridin-2-il-aminoalquilcarbonilglicil-beta-alanina y derivados del mismo.
DK0623112T3 (da)	1999-08-30	4-phenyl-3-(heteroarylureido)-1,2-dihydro-2-oxoquinolinderivater som antihypercholesterolæmiske og antiatherosclerotiske mi
CO4930270A1 (es)	2000-06-27	Derivados heterociclicos de acido carbonico su produccion y aplicacion como antagonistas de receptores deendotelina

Legal Events

Date	Code	Title	Description
2002-04-30	A1OB	Publication of a patent application
2002-06-17	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2006-10-31	B1PR	Patent granted
2008-08-22	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20080822 Year of fee payment: 10
2010-03-11	PBON	Lapse due to non-payment of renewal fee	Effective date: 20090911